Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Julianne Chen"'
Autor:
Partow Kebriaei, Julianne Chen, Demetrios Petropoulos, Muzaffar H. Qazilbash, Richard E. Champlin, Samer A. Srour, Jeremy Ramdial, Gabriela Rondon, Piyanuch Kongtim, Elizabeth J. Shpall, Uday R. Popat, Stefan O. Ciurea
Publikováno v:
American Journal of Hematology. 95:1187-1192
Relapse after allogeneic hematopoietic stem-cell transplantation (AHSCT) is associated with very poor outcomes. A second transplant offers the possibility of long-term disease control. We analyzed outcomes with haploidentical donors for second allogr
Autor:
Panupong Hansrivijit, Julianne Chen, Sharon R. Hymes, Uday R. Popat, Stefan O. Ciurea, Richard E. Champlin, Gabriela Rondon, Ana M. Ciurea, Chitra Hosing
Publikováno v:
American Journal of Hematology. 94:E176-E180
Autor:
Stefan O. Ciurea, Oran Betul, Julianne Chen, Maria C.B. Bittencourt, Richard E. Champlin, Samer A. Srour, Jeremy Ramdial, Gabriela Rondon, Partow Kebriaei, Uday R. Popat, Elizabeth J. Shpall, Qaiser Bashir, Piyanuch Kongtim, Amanda Olson, Issa F. Khouri
Publikováno v:
American Journal of Hematology. 95
Autor:
Partow Kebriaei, Jonathan E. Brammer, Sameh Gaballa, Rima M. Saliba, Michael Andreeff, Farhad Ravandi, Uday R. Popat, Jorge E. Cortes, Julianne Chen, Naval Daver, Stefan O. Ciurea, Gabriela Rondon, Amin M. Alousi, Keyur P. Patel, Elias Jabbour, David Marin, Richard E. Champlin, Betul Oran, Elizabeth J. Shpall, Borje S. Andersson
Publikováno v:
American Journal of Hematology. 92:331-337
In patients with AML with FMS-like tyrosine kinase 3 (FLT3) mutations, the significance of minimal residual disease (MRD) detected by PCR before allogeneic stem cell transplantation (SCT) on outcomes after transplant remains unclear. We identified 20
Autor:
Naval Daver, Julianne Chen, Guillermo Garcia-Manero, Gabriela Rondon, Issa F. Khouri, Hagop M. Kantarjian, Uday R. Popat, Richard E. Champlin, Marcos de Lima, Sergio Giralt, Betul Oran, Maria Tanaka, Sherry Pierce, Ebru Koca, Simrit Parmar, Elias Jabbour, Michael S. Mathisen, Tapan M. Kadia
Publikováno v:
American Journal of Hematology. 88:198-200
Allogeneic stem cell transplantation (allo-SCT) is the only potentially curative treatment for myelodysplastic syndrome (MDS). Recently, hypomethylating agents (HMAs) have been shown to improve survival in patients with high-risk MDS. We conducted a